Home › Research › Topics › donepezil
donepezil
271 studies tagged donepezil, dated 1981-01-01 to 2026-10-14. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
271 studies carry this tag.
Date range
1981 to 2026
Top journals
- Journal of Alzheimer's disease : JAD 15
- Neurology 11
- Journal of the American Geriatrics Society 9
- Research Square 8
- medRxiv 8
138 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
No difference was seen in Clinical Global Impression scores between patients receiving placebo and those receiving linopirdine (n = 189).
-
It has been suggested that patients undergoing treatment with recombinant interleukin-2 (rIL-2) may develop cognitive impairment.
-
This study evaluated the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer's disease, and examined the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase (AChE) activity and clinical response.
-
The efficacy of the ginkgo biloba special extract EGb 761 in outpatients with presenile and senile primary degenerative dementia of the Alzheimer type (DAT) and multi-infarct dementia (MID) according to DSM-III-R was investigated in a prospective, randomized, double-blind, placebo-controlled, multi-center study.
-
Overall, less than half of patients diagnosed with schizophrenia have shown substantial clinical improvement after follow-up averaging nearly 6 years.
-
Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%).
-
Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life.
-
In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group.
-
These results confirm the efficacy and safety of tacrine in some patients with Alzheimer's disease.
-
In this short-term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine, treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients.
-
1. Dementia: Significance, Definition, and Epidemiology 2.
-
Increasing attention is being paid to inappropriate medication use in nursing homes.
-
In this multicenter study, the clinical efficacy of citalopram was investigated in 98 patients with moderate AD/SDAT or VD using a combined double-blind and open technique with placebo and citalopram.
-
We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT).
-
Prior qualitative literature reviews about the use of neuroleptics in dementia suggest that they are "modestly effective" in treating agitation and that no single neuroleptic is better than another.
-
To determine if the risk of hip fracture difference between persons receiving benzodiazepines with long (greater than or equal to 24 hours) or short (less than 24 hours) elimination half-lives, we conducted a nested case-control study among residents of the Canadian province of Saskatchewan who were 65 years of age and older.
-
Adverse drug reactions causing cognitive impairment are an important problem in the elderly.
-
Limited information is available regarding the incidence, nature, and treatment of behavioral problems in Alzheimer's disease (AD).
-
To assess the risk of hip fracture associated with the use of four classes of psychotropic drugs, we performed a case-control study of 1021 patients with hip fractures and 5606 controls among elderly Medicaid enrollees.
-
We treated 17 patients who had moderate to severe Alzheimer's disease with oral tetrahydroaminoacridine (THA), a centrally active anticholinesterase, in a three-phase study.
-
43/100
Physostigmine (0.25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia.
From across this tag
8 of the 271 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia
- Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
- The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
- Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial
- A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
- Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
- Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study
- Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer’s Disease